Recent advances in understanding myelofibrosis and essential thrombocythemia

F1000Research

Volumn 5, Issue , 2016, Pages

  Vainchenker, William ^a,b   Constantinescu, Stefan N ^c,d   Plo, Isabelle ^a,b  

^a Institute Gustav Roussy   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d DE DUVE INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 33; INTERLEUKIN 8; JANUS KINASE 2; REACTIVE OXYGEN METABOLITE; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AGING; ALLELE; ANEMIA; CLINICAL FEATURE; COMORBIDITY; CYTOKINE RELEASE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; EXON; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HEREDITY; HUMAN; INFLAMMATION; MOLECULAR CLONING; MYELOID METAPLASIA; NONHUMAN; PATHOGENESIS; PHENOTYPE; REVIEW; SEQUENCE ANALYSIS; SEX DIFFERENCE; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA; TUMOR MICROENVIRONMENT;

EID: 84978493456     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.8081.1     Document Type: Review

References (94)

1. Spivak JL: The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol. 2004;41(2 Suppl 3):1-5. 15190515 10.1053/j.seminhematol.2004.02.011
2. Tefferi A Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22. 17882280 10.1038/sj.leu.2404955 F1000 Recommendation
3. Barosi G Ambrosetti A Finelli C: The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104(4):730-7. 10192432 10.1046/j.1365-2141.1999.01262.x
4. Tefferi A Barbui T: Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia. 2013;27(8):1617-20. 23558521 10.1038/leu.2013.99 3740400 F1000 Recommendation
5. Baxter EJ Scott LM Campbell PJ: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-61. 15781101 10.1016/S0140-6736(05)71142-9 F1000 Recommendation
6. James C Ugo V Le Couédic JP: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8. 15793561 10.1038/nature03546 F1000 Recommendation
7. Kralovics R Passamonti F Buser AS: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90. 15858187 10.1056/NEJMoa051113 F1000 Recommendation
8. Levine RL Wadleigh M Cools J: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-97. 15837627 10.1016/j.ccr.2005.03.023 F1000 Recommendation
9. Shan Y Gnanasambandan K Ungureanu D: Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. Nat Struct Mol Biol. 2014;21(7):579-84. 24918548 10.1038/nsmb.2849 4508010 F1000 Recommendation
10. Scott LM Tong W Levine RL: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-68. 17267906 10.1056/NEJMoa065202 2873834 F1000 Recommendation
11. Pikman Y Lee BH Mercher T: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270. 16834459 10.1371/journal.pmed.0030270 1502153 F1000 Recommendation
12. Defour JP Chachoua I Pecquet C: Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. Leukemia. 2015. 26437785 10.1038/leu.2015.271
13. Pardanani AD Levine RL Lasho T: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-6. 16868251 10.1182/blood-2006-04-018879
14. Ding J Komatsu H Wakita A: Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198-200. 14764528 10.1182/blood-2003-10-3471 F1000 Recommendation
15. Oh ST Simonds EF Jones C: Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116(6):988-92. 20404132 10.1182/blood-2010-02-270108 2924231
16. Klampfl T Gisslinger H Harutyunyan AS: Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-90. 24325356 10.1056/NEJMoa1311347 F1000 Recommendation
17. Nangalia J Massie CE Baxter EJ: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-405. 24325359 10.1056/NEJMoa1312542 3966280 F1000 Recommendation
18. Michalak M Groenendyk J Szabo E: Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J. 2009;417(3):651-66. 19133842 10.1042/BJ20081847
19. Chachoua I Pecquet C El-Khoury M: Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127(10):1325-1335. 26668133 10.1182/blood-2015-11-681932 F1000 Recommendation
20. Marty C Pecquet C Nivarthi H: Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127(10):1317-24. 26608331 10.1182/blood-2015-11-679571 F1000 Recommendation
21. Garbati MR Welgan CA Landefeld SH: Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. Am J Hematol. 2016;91(2):211-9. 26573090 10.1002/ajh.24245
22. Rampal R Al-Shahrour F Abdel-Wahab O: Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123-33. 24740812 10.1182/blood-2014-02-554634 4041169
23. Cabagnols X Favale F Pasquier F: Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127(3):333-42. 26450985 10.1182/blood-2015-07-661983
24. Milosevic Feenstra JD Nivarthi H Gisslinger H: Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127(3):325-32. 26423830 10.1182/blood-2015-07-661835 4752213
25. Sultan C Sigaux F Imbert M: Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol. 1981;49(1):11-6. 7272222 10.1111/j.1365-2141.1981.tb07191.x
26. Hasan S Lacout C Marty C: JAK2 V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood. 2013;122(8):1464-77. 23863895 10.1182/blood-2013-04-498956
27. Lacout C Pisani DF Tulliez M: JAK2 V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-60. 16670266 10.1182/blood-2006-02-002030
28. Li J Kent DG Godfrey AL: JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. Blood. 2014;123(20):3139-51. 24692758 10.1182/blood-2013-06-510222 F1000 Recommendation
29. Tiedt R Coers J Ziegler S: Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood. 2009;113(8):1768-77. 18845793 10.1182/blood-2008-03-146084 F1000 Recommendation
30. Villeval JL Cohen-Solal K Tulliez M: High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90(11):4369-83. 9373248
31. Yan XQ Lacey D Hill D: A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88(2):402-9. 8695786
32. Lundberg P Takizawa H Kubovcakova L: Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014;211(11):2213-30. 25288396 10.1084/jem.20131371 4203945 F1000 Recommendation
33. Dupont S Massé A James C: The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110(3):1013-21. 17389763 10.1182/blood-2006-10-054940
34. 617F-induced myeloproliferative neoplasm. Blood. 2014;124(26):3956-63. 25339357 10.1182/blood-2014-07-587238 4271181 F1000 Recommendation
35. Cabagnols X Defour JP Ugo V: Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia. 2015;29(1):249-52. 25212275 10.1038/leu.2014.270
36. Tefferi A Pardanani A: Genetics: CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol. 2014;11(3):125-6. 24514146 10.1038/nrclinonc.2014.16 F1000 Recommendation
37. Rumi E Pietra D Ferretti V: JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544-51. 24366362 10.1182/blood-2013-11-539098 3945864 F1000 Recommendation
38. Bartalucci N Tozzi L Bogani C: Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. J Cell Mol Med. 2013;17(11):1385-96. 24237791 10.1111/jcmm.12162 4117551 F1000 Recommendation
39. Choong ML Pecquet C Pendharkar V: Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. J Cell Mol Med. 2013;17(11):1397-409. 24251790 10.1111/jcmm.12156 4117552
40. Chen E Beer PA Godfrey AL: Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18(5):524-35. 21074499 10.1016/j.ccr.2010.10.013 2996868 F1000 Recommendation
41. Duek A Lundberg P Shimizu T: Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood. 2014;123(25):3943-50. 24820309 10.1182/blood-2013-07-514208 F1000 Recommendation
42. Grisouard J Shimizu T Duek A: Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 2015;125(13):2131-40. 25595737 10.1182/blood-2014-08-594572 F1000 Recommendation
43. Yan D Hutchison RE Mohi G: Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood. 2012;119(15):3539-49. 22144185 10.1182/blood-2011-03-345215 3325041 F1000 Recommendation
44. Pietra D Rumi E Ferretti VV: Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431-8. 26449662 10.1038/leu.2015.277 4740452 F1000 Recommendation
45. Delhommeau F Dupont S Della Valle V: Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-301. 19474426 10.1056/NEJMoa0810069 F1000 Recommendation
46. Gelsi-Boyer V Trouplin V Adélaïde J: Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788-800. 19388938 10.1111/j.1365-2141.2009.07697.x
47. Lundberg P Karow A Nienhold R: Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220-8. 24478400 10.1182/blood-2013-11-537167
48. Yoshida K Sanada M Shiraishi Y: Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-9. 21909114 10.1038/nature10496 F1000 Recommendation
49. Abdel-Wahab O Manshouri T Patel J: Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447-52. 20068184 10.1158/0008-5472.CAN-09-3783 2947340 F1000 Recommendation
50. Harutyunyan A Klampfl T Cazzola M: p53 lesions in leukemic transformation. N Engl J Med. 2011;364(5):488-90. 21288114 10.1056/NEJMc1012718 F1000 Recommendation
51. Klampfl T Harutyunyan A Berg T: Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011;118(1):167-76. 21531982 10.1182/blood-2011-01-331678
52. Zhang SJ Rampal R Manshouri T: Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119(19):4480-5. 22431577 10.1182/blood-2011-11-390252 3362363
53. Itzykson R Kosmider O Renneville A: Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428-36. 23690417 10.1200/JCO.2012.47.3314 F1000 Recommendation
54. Kosmider O Gelsi-Boyer V Cheok M: TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114(15):3285-91. 19666869 10.1182/blood-2009-04-215814 F1000 Recommendation
55. Vannucchi AM Lasho TL Guglielmelli P: Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-9. 23619563 10.1038/leu.2013.119
56. Jaiswal S Fontanillas P Flannick J: Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-98. 25426837 10.1056/NEJMoa1408617 4306669 F1000 Recommendation
57. Xie M Lu C Wang J: Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472-8. 25326804 10.1038/nm.3733 4313872 F1000 Recommendation
58. Nangalia J Nice FL Wedge DC: DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica. 2015;100(11):e438-42. 26250577 10.3324/haematol.2015.129510 F1000 Recommendation
59. Ortmann CA Kent DG Nangalia J: Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601-12. 25671252 10.1056/NEJMoa1412098 4660033 F1000 Recommendation
60. Beer PA Delhommeau F LeCouédic JP: Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115(14):2891-900. 20008300 10.1182/blood-2009-08-236596
61. Theocharides A Boissinot M Girodon F: Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110(1):375-9. 17363731 10.1182/blood-2006-12-062125
62. Castro-Malaspina H Rabellino EM Yen A: Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood. 1981;57(4):781-7. 7470627
63. Wagner-Ballon O Chagraoui H Prina E: Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin. J Immunol. 2006;176(11):6425-33. 16709799 10.4049/jimmunol.176.11.6425
64. Chagraoui H Komura E Tulliez M: Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100(10):3495-503. 12393681 10.1182/blood-2002-04-1133
65. Le Bousse-Kerdilès MC Chevillard S Charpentier A: Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996;88(12):4534-46. 8977245
66. Barosi G: Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. Best Pract Res Clin Haematol. 2014;27(2):129-40. 25189724 10.1016/j.beha.2014.07.004
67. Quivoron C Couronné L Della Valle V: TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25-38. 21723201 10.1016/j.ccr.2011.06.003 F1000 Recommendation
68. Tefferi A Finke CM Lasho TL: U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia. 2014;28(2):431-3. 24097336 10.1038/leu.2013.286 F1000 Recommendation
69. Sánchez-Aguilera A Arranz L Martín-Pérez D: Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell. 2014;15(6):791-804. 25479752 10.1016/j.stem.2014.11.002 F1000 Recommendation
70. Campbell PJ: Somatic and germline genetics at the JAK2 locus. Nat Genet. 2009;41(4):385-6. 19338077 10.1038/ng0409-385
71. Jones AV Chase A Silver RT: JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-9. 19287382 10.1038/ng.334 4120192 F1000 Recommendation
72. Olcaydu D Harutyunyan A Jäger R: A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-4. 19287385 10.1038/ng.341 F1000 Recommendation
73. Soler G Bernal-Vicente A Antón AI: The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms. Ann Hematol. 2015;94(5):789-94. 25482455 10.1007/s00277-014-2266-y F1000 Recommendation
74. Tapper W Jones AV Kralovics R: Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015;6:6691. 25849990 4396373
75. Harutyunyan AS Jäger R Chen D: Allelic imbalance in CALR somatic mutagenesis. Leukemia. 2015;29(6):1431-5. 25567134 10.1038/leu.2015.3 4430307
76. Eder-Azanza L Evans P Wickham C: Constitutional genetic association with CALR mutations? Leukemia. 2015;29(12):2410-1. 26198293 10.1038/leu.2015.186
77. Saliba J Saint-Martin C Di Stefano A: Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat Genet. 2015;47(10):1131-40. 26280900 10.1038/ng.3380 F1000 Recommendation
78. Tefferi A Vaidya R Caramazza D: Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-63. 21300928 10.1200/JCO.2010.32.9490 F1000 Recommendation
79. Geyer HL Dueck AC Scherber RM: Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. Mediators Inflamm. 2015;2015: 284706. 26538823 10.1155/2015/284706 4619953 F1000 Recommendation
80. Fleischman AG Aichberger KJ Luty SB: TNFα facilitates clonal expansion of JAK2 V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392-8. 21860020 10.1182/blood-2011-04-348144 3236121
81. Hasselbalch HC: Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Rev Hematol. 2014;7(2):203-16. 24524202 10.1586/17474086.2013.876356
82. Ferrer-Marín F Amigo ML Vicente V: Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors. Clin Drug Investig. 2012;32(6):423-6. 22550963 10.2165/11599850-000000000-00000
83. Kurzrock R: The role of cytokines in cancer-related fatigue. Cancer. 2001;92(6 Suppl):1684-8. 11598887 10.1002/1097-0142(20010915)92:6+<1684::AID-CNCR1497>3.0.CO;2-Z
84. Meyers CA Albitar M Estey E: Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4):788-93. 15973668 10.1002/cncr.21234
85. Pardanani A Finke C Abdelrahman RA: Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013;88(4):312-6. 23450619 10.1002/ajh.23406 F1000 Recommendation
86. Kleppe M Kwak M Koppikar P: JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5(3):316-31. 25572172 10.1158/2159-8290.CD-14-0736 4355105 F1000 Recommendation
87. Arranz L Sánchez-Aguilera A Martín-Pérez D: Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014;512(7512):78-81. 25043017 10.1038/nature13383 F1000 Recommendation
88. Martinaud C Desterke C Konopacki J: Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis. Cancer Res. 2015;75(22):4753-65. 26404004 10.1158/0008-5472.CAN-14-3696 F1000 Recommendation
89. Martinaud C Desterke C Konopacki J: Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis. Genom Data. 2015;5:1-2. 26484208 10.1016/j.gdata.2015.04.017 4583614 F1000 Recommendation
90. Sozer S Fiel MI Schiano T: The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246-9. 19293426 10.1182/blood-2008-11-191544 2686192 F1000 Recommendation
91. Desterke C Bilhou-Nabéra C Guerton B: FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. Cancer Res. 2011;71(8):2901-15. 21487043 10.1158/0008-5472.CAN-10-1731
92. Mager LF Riether C Schürch CM: IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J Clin Invest. 2015;125(7):2579-91. 26011644 10.1172/JCI77347 4563674 F1000 Recommendation
93. Raaijmakers MH Mukherjee S Guo S: Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464(7290):852-7. 20305640 10.1038/nature08851 3422863 F1000 Recommendation
94. Marty C Lacout C Droin N: A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia. 2013;27(11):2187-95. 23558526 10.1038/leu.2013.102